The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | Novel approaches for the treatment of myelofibrosis: navitoclax + ruxolitinib
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives a brief overview of novel treatment approaches in myelofibrosis (MF), drawing focus on a recent study investigating the use of navitoclax with ruxolitinib in patients with MF. Dr Pemmaraju highlights an ongoing study investigating this treatment combination, and thinking about disease modification in MF. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
